VC  Syneptics

     Office Locations:

4861 Lone Oak Ct.
Ann Arbor, MI 48108
Phone: 734-945-1727



  • Early



  • Information Technology



    Syneptics makes early stage investments of up to $250,000 in small but growing companies. The firm looks for interesting products with compelling markets where early capital will provide a clearly defined jump to the next level. Syneptics seeks opportunities where its principal can be returned in 24 months or less. Syneptics invests primarily in new technologies. Syneptics is primarily the venture financing vehicle for Bill Orabone, a veteran of four successful technology startups which have resulted in over $400 million in exit valuations: Memcor (microfiltration); Harding Energy (nickel metal hydride batteries); Intract (manufacturing equipment); and Lion Compact Energy (dual graphite batteries).

    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Growth Stage
    (also called Mid-stage)
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B

    Investment Team:

    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Bill Orabone President


    Portfolio companies include:

        web link

      TJ Pulse
        web link

      Ultimate Air
        web link

      Velcura Therapeutics
        web link


    Recent News:

      There is no recent news for Syneptics.